In a patient with lung cancer who has multifocal jejunal masses, how should the jejunal lesions be evaluated to determine if they represent metastases versus a second primary, and what first‑line systemic therapy is recommended based on molecular profiling?

Evaluation and Management of Jejunal Masses in Lung Cancer Patients

In a patient with lung cancer and multifocal jejunal masses, obtain tissue from the jejunal lesions for histopathology with immunohistochemistry (TTF-1, CK7, CK20, CDX2, napsin A) to definitively distinguish lung metastases from a second primary jejunal adenocarcinoma, then proceed with molecular profiling (EGFR, ALK, ROS1, PD-L1) to guide first-line systemic therapy. 1, 2

Diagnostic Approach to Jejunal Lesions

The critical first step is determining whether these jejunal masses represent metastases from the lung cancer versus a synchronous second primary. This distinction fundamentally alters staging, prognosis, and treatment strategy.

Tissue Acquisition and Pathologic Evaluation

Biopsy the jejunal lesions using the least invasive feasible method—endoscopy with biopsy if accessible, or image-guided biopsy 3. The guideline framework emphasizes that when multiple potential metastatic sites exist, tissue confirmation should be obtained from the site that would confer the highest stage 3.

Immunohistochemical Panel for Primary Site Determination

The pathologic distinction relies heavily on immunohistochemistry 1:

Lung adenocarcinoma metastases typically show:

• TTF-1 positive (strong, diffuse)
• CK7 positive
• CK20 negative
• Napsin A positive
• CDX2 negative

Primary jejunal adenocarcinoma typically shows:

• TTF-1 negative
• CK7 variable
• CK20 positive
• CDX2 positive
• Napsin A negative

This immunoprofile provides approximately 90% accuracy in distinguishing lung from gastrointestinal primaries 1. Case reports confirm this approach successfully differentiated synchronous lung and jejunal primaries 4.

Additional Diagnostic Considerations

• Histologic architecture matters: Lung metastases tend to show infiltrative growth patterns, while primary GI tumors often demonstrate more expansile growth 1
• Clinical context: Jejunal metastases from lung cancer are rare but increasingly recognized, often presenting with obstruction or bleeding 5, 6, 7, 8
• Molecular profiling: If available, comprehensive genomic profiling can definitively establish clonal relationships between tumors 9, 10

Staging Implications

If jejunal lesions are metastases: The patient has stage IV (M1b) disease with distant metastases 11, 3. This carries significantly worse prognosis and mandates systemic therapy as primary treatment.

If jejunal lesions represent a second primary: Each tumor should be staged independently with separate TNM classifications 3, 9. Management is dictated by each tumor individually, provided the patient has adequate functional reserve 3.

First-Line Systemic Therapy Based on Molecular Profiling

Once metastatic lung cancer is confirmed, comprehensive molecular testing must be performed immediately before initiating systemic therapy 11, 2.

Required Molecular Testing

Test for the following actionable mutations in all advanced non-squamous NSCLC 11, 2:

1. EGFR mutations (exons 18-21, including sensitizing mutations)
2. ALK rearrangements (by FISH or validated IHC)
3. ROS1 rearrangements
4. PD-L1 expression (by validated IHC assay)

Additional biomarkers (BRAF V600E, MET exon 14 skipping, NTRK fusions, RET fusions, KRAS G12C) should be tested if comprehensive NGS is available 2, 12.

First-Line Therapy Selection Algorithm

For EGFR-mutated NSCLC:

• First-line TKI therapy (osimertinib preferred for common mutations) 11, 12
• Do NOT use chemotherapy first-line in EGFR-mutated disease

For ALK-rearranged NSCLC:

• First-line ALK TKI (alectinib or brigatinib preferred) 11, 12

For ROS1-rearranged NSCLC:

• First-line ROS1 TKI (entrectinib or crizotinib) 2, 12

For driver-negative NSCLC with PD-L1 ≥50%:

• Pembrolizumab monotherapy is an option 12

For driver-negative NSCLC (any PD-L1 level):

• Platinum-based doublet chemotherapy plus pembrolizumab is the standard first-line approach 11, 13
• For non-squamous histology: Pemetrexed + platinum (cisplatin preferred) + pembrolizumab 11, 13
• Alternative: Carboplatin + paclitaxel + pembrolizumab 13
• Bevacizumab may be added to platinum-doublet in eligible patients (PS 0-1, non-squamous, no contraindications) 11

Performance Status Considerations

PS 0-1: Standard platinum doublet with immunotherapy 11, 13

PS 2:

• If PS 2 is cancer-related: Consider platinum doublet chemotherapy 3
• Single-agent chemotherapy is acceptable alternative 11
• Do NOT add bevacizumab in PS ≥2 patients 3

PS 3-4: Best supportive care unless actionable mutation present 11

Critical Pitfalls to Avoid

1. Do not assume jejunal masses are metastatic without tissue confirmation—synchronous primaries occur and require different management 3, 9

2. Do not delay molecular testing—parallel testing is preferable to sequential testing to avoid treatment delays 11. Results should be available within 2 weeks 2

3. Do not use EGFR IHC or EGFR copy number (FISH) to select patients for EGFR TKI therapy—these are not validated predictive biomarkers 2

4. Do not start chemotherapy before molecular results in non-squamous NSCLC—unless the patient is clinically deteriorating and cannot wait 11

5. Do not use pemetrexed in squamous histology—it is ineffective and potentially harmful 11

6. Recognize that GI metastases from lung cancer indicate aggressive disease with poor prognosis regardless of treatment approach 5, 6, 8

Multidisciplinary Evaluation

All treatment decisions should be discussed within a multidisciplinary tumor board including medical oncology, thoracic surgery, radiation oncology, pulmonology, gastroenterology, radiology, and pathology 11, 3. This is particularly crucial for complex presentations like synchronous malignancies.